Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences, Inc. provides grants for projects that make a significant impact in core therapeutic areas: HIV, liver disease (including HCV, HBV, HDV), oncology (hematology and solid tumors), and inflammatory and respiratory diseases. The grant program values applications that show a strong commitment and capacity for delivering services supported by the grant. Gilead funds a diversity of projects, including patient community support efforts aimed at raising awareness about disease prevention and care, and medical and scientific support projects that offer continuing education for healthcare professionals. The program is open to various organizations, such as patient advocacy groups, hospitals, clinics, non-profit service organizations, professional associations, academic medical centers, and universities. Additionally, Gilead Europe Grants focus on the same core therapeutic areas, providing support for activities like disease awareness, prevention, professional education, and improving access and quality of care, without specifying minimum or maximum funding request amounts.